.svg){kind=logo}
Schizophrenia is a complex mental health condition that affects about 1 in 100 people in the UK. It can cause hallucinations (seeing or hearing things that aren't there) and delusions (fixed, false beliefs). Additionally, people with schizophrenia may experience social withdrawal, difficulty concentrating, and disorganized thinking.
Schizophrenia is typically treated with a combination of medication and therapy. Antipsychotic medications are the mainstay of treatment, helping to manage symptoms like hallucinations and delusions. Therapy, such as cognitive behavioral therapy (CBT), can equip individuals with coping mechanisms and improve social skills. However, finding the right medication and therapy approach can be a process of trial and error, and some people experience side effects from medications.
MeOmics is transforming the future of schizophrenia treatment by offering a more personalized approach. We analyze a patient's unique biology, including: Cellular activity How their nerve cells respond to stimuli. Genetics Their genetic makeup to understand potential risk factors. By integrating this information with a patient's medical history,
MeOmics aims to predict the most effective medications for their specific needs. This personalized approach has the potential to: Reduce trial-and-error with medication Finding the right medication faster can lead to quicker symptom relief and improved quality of life. Minimize side effects: Matching the right medication to a patient's biology can potentially reduce the risk of unwanted side effects. Empower patients: Being actively involved in a personalized treatment plan can lead to a greater sense of control and hope for recovery.
If you or someone you know is experiencing symptoms of schizophrenia, it's important to seek professional help. Here are some resources available in the UK:
